Galecto, Inc. (GLTO) Stock Price, Financial Report, & Fundamental Analysis
NASDAQ:GLTOGalecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis.
(0.6)
Galecto, Inc. Fundamental Analysis
Strength
| Analysis | # |
|---|---|
Price to Book (PBV) RatioUndervalued price-to-book. GLTO stock price is under 1x the price-to-book value. |
|
Debt-Equity Ratio (DER)GLTO equity is higher than it's debt. |
Weakness
| Analysis | # |
|---|---|
Market CapSmall market capitalization. Market capitalization is less than 2bn USD |
|
Revenue GrowthGLTO has never had growing revenue. |
|
Net Income GrowthGLTO has never had growing net income. |
|
Net IncomeGLTO never has positive net income for 2 years. |
|
Dividend YieldGLTO has low dividend yield (0%). |
|
Return of AssetsGLTO has low return of asset (-74.32%). |
|
Return of EquityGLTO has low return of equity (-64.8%). |
|
RevenueGLTO never has positive revenue for 2 years. |
|
Return of Invested CapitalGLTO has low ROIC. |
Competitors
Galecto, Inc. Financials
Financial statements are written records that convey the business activities and the financial performance of a company. Financial statements include the balance sheet, income statement, and statement of cash flow.
Income Statement
Also known as the profit and loss (P&L) statement or the statement of revenue and expense, the income statement primarily focuses on the company’s revenue and expenses during a particular period.
- Revenue
- 0 USD
- Cost
- 52,227,000 USD
- Net Income
- -51,752,000 USD
- Profit Margin
- 0%
Cashflow Statement
A cash flow statement is a financial statement that provides aggregate data regarding all cash inflows a company receives from its ongoing operations and external investment sources. It also includes all cash outflows that pay for business activities and investments during a given period.
- Free Cash Flow
- -52,531,000 USD
Balance Sheet
Liquidity & Solvency
Solvency refers to an company's capacity to meet its long-term financial commitments. Liquidity refers to an company's ability to pay short-term obligations. The term also refers to a company's capability to sell assets quickly to raise cash.
Short Term Liabilities
| Quick Ratio | 792.23% |
Long Term Liabilities
| Liquidity/Current Ratio | 803.78% |
Dividend
| Dividend Yield | 0% |
| Dividend Payout Ratio (DPR) | 0% |
| Dividend Payout Ratio (DPR) | 0% |
| Dividend per Share | 0,00 USD |
Financial Ratios
| Price to Earning (PER) | -0.5x |
| Price to Earning-Growth (PEG) | 0x |
| Price to Book Value (PBV) | 0x |
| Liquidity/Current Ratio | 803.78% |
| Cash Ratio | 319.89% |
| Debt Ratio | 11.34% |
| Debt-Equity Ratio (DER) | 12.78% |
| Net Profit Margin (NPM) | 0% |
| Return of Assets (ROA) | -74.32% |
| Return of Equity (ROE) | -64.8% |
| Return on Capital Employed (ROCE) | -83.58% |
| Days of Sales Outstanding (DSO) | 0 |
| Days of Inventory Outstanding (DIO) | 0 |
| Days Payable Outstanding (DPO) | 0 |
| Operating Cycle (OC) | 0 |
| Cash Conversion Cycle (CCC) | 0 |
Galecto, Inc. Executives
CEO
- CEO Name
- Dr. Hans T. Schambye
Management
Galecto, Inc. Profile
About Galecto, Inc.
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.
Additional Information
- Company name
- Galecto, Inc.
- Symbol
- NASDAQ:GLTO
- Exchange
- NASDAQ Global Select
- Industry
- Biotechnology
- Sector
- Healthcare
- Address
-
Ole Maaloes Vej 3
Copenhagen
DK
02109 - Website
- https://galecto.com